|
Andrew
Whiteley has over 30 years experience of strategic management and marketing of leading edge technologies to the Life
Science industry. Andrew is currently the Head of the Office of Technology Transfer at Cold Spring Harbor Laboratory, situated
on Long Island New York, and is responsible for all commercialization of technology from the talented scientists of CSHL.
Previously, Andrew worked at the Lustgarten Foundation for Cancer Research. Prior to that Andrew was Chief Operating Officer
at Enzo Life Sciences, the head of the product division of Enzo Biochem Inc. (NYSE: ENZ), and was previously CEO of Vitra
Bioscience, the developer of CellPlex assays for drug candidate profiling. Andrew was also Chairman and CEO of InforMax Inc
(NASDAQ: INMX), the leading supplier of Bioinformatics analysis tools. He was responsible for the restructuring and sale of
the company to Invitrogen.
Prior to Vitra Bioscience, Andrew had an extensive career at Amersham Biosciences initially
in Europe including Business Manager for Central Europe and Head of Strategic Marketing for Cell Biology and Molecular Biology
products. Andrew moved to the United States in 1996 to become Site Director for Amersham’s Cleveland site, where he
oversaw the successful transition of the Sequencing business to New Jersey. He then moved to the West Coast as VP of Sequencing
at Molecular Dynamics. Andrew was responsible for the launch and first year sales of the MegaBACE DNA sequencer. Andrew became
VP of Bioinformatics to build this new business area and during this time served as external board director to InforMax Inc,
Cimarron Software and Imaging Research Inc.
Andrew graduated from Nottingham University in the UK with an honors
degree in Biochemistry and Chemistry.
|
